Novel Targets and Approaches in Cancer Therapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 50018
Special Issue Editor
Interests: computational cancer genomics; next generation sequencing; targeted therapy; immunotherapy; target discovery; drug repurposing; rare cancers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Novel targeted therapies and immunotherapies have revolutionized the treatment of various tumor types. The development of next-generation sequencing technologies plays a key role in identifying new targets and advancing precision oncology. Novel targets are still needed to optimize current therapies, identify effective combinations, improve efficacy and address acquired resistance. Furthermore, new innovative strategies are also needed for rare cancers, where the availability of sequencing and other data may be limiting. In this Special Issue of Cancers, we invite research manuscripts and reviews that present novel or improved targets and drugs, new insights into current cancer therapies and related mechanisms, as well as new methods, databases and tools that aid in the identification of targets and the development of targeted therapies and immunotherapies.
Dr. Jason Roszik
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted therapy
- immunotherapy
- cancer
- target discovery
- personalized medicine
- precision oncology
- rare cancers
- large databases
- data analytics tools
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.